NCT07577505 Histidine Supplementation for Antitumor Immunity in Colorectal Cancer
| NCT ID | NCT07577505 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Jing-yuan Fang, MD, Ph. D |
| Condition | Colorectal Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2026-05-06 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2026-05-06 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical study is to learn whether oral histidine supplementation may be safely used to support antitumor immune function during standard colorectal cancer treatment. Participants with colorectal cancer in the supplementation group will: Take 2g oral histidine once daily during standard colorectal cancer treatment; Provide blood samples before and after supplementation; Attend regular follow-up visits for laboratory tests, safety assessment, and treatment evaluation.
Eligibility Criteria
Inclusion Criteria: 1. Patients aged 18-80 years, regardless of sex. 2. Body mass index (BMI) ≥18.5. 3. NRS-2002 score \<3. 4. Diagnosed with stage II or higher colorectal cancer who require pharmacological intervention. 5. Capable of oral intake of medication. 6. Willing to participate in the study and provide written informed consent. Exclusion Criteria: 1. Participation in other interventional clinical trials (including drugs, nutritional supplements, medical devices, etc.) within 4 weeks prior to enrollment. 2. Presence of ascites, severe diarrhea, intractable vomiting, severe malabsorption syndrome, paralysis, mechanical intestinal obstruction, or active gastrointestinal bleeding. 3. Allergy to sample components. 4. Current use of other nutritional supplements that may affect the validity and effectiveness of the study results. 5. Pregnant, lactating female patients or women with fertility who test positive in the baseline pregnancy test. 6. Presence of cognitive impairments or mental illnesses that prevent understanding of the study procedures. 7. Presence of any other conditions, judged by the researcher, make the participant unsuitable for participation in the study.
Contact & Investigator
Jing-Yuan Fang, M.D.
STUDY DIRECTOR
Division of Gastroenterology and Hepatology, NHC Key Laboratory of Digestive Diseases, Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Frequently Asked Questions
Who can join the NCT07577505 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Colorectal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07577505 currently recruiting?
Yes, NCT07577505 is actively recruiting participants. Contact the research team at duwan2017@126.com for enrollment information.
Where is the NCT07577505 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT07577505 clinical trial?
NCT07577505 is sponsored by Jing-yuan Fang, MD, Ph. D. The principal investigator is Jing-Yuan Fang, M.D. at Division of Gastroenterology and Hepatology, NHC Key Laboratory of Digestive Diseases, Renji Hospital, School of Medicine, Shanghai Jiao Tong University. The trial plans to enroll 20 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.